A dendritic cell(DC)vaccine strategy has been developed as a new cancer immunotherapy,but the goal of complete tumor eradication has not yet been achieved.We have previously shown that baculoviruses potently infect DC...A dendritic cell(DC)vaccine strategy has been developed as a new cancer immunotherapy,but the goal of complete tumor eradication has not yet been achieved.We have previously shown that baculoviruses potently infect DCs and induce antitumor immunity against hepatomas in a mouse model.Baculovirus-infected,bone marrow-derived DCs(BMDCs)display increased surface expression of costimulatory molecules,such as CD80,CD86 and major histocompatibility complex(MHC)classes I and II,and secrete interferons and other proinflammatory cytokines.In this study,we evaluated the induction of antitumor immunity in mice by baculovirus-infected BMDCs against lung cancer and melanoma.After treatment with baculovirus-infected BMDCs,murine lung tumors caused by Lewis lung carcinoma(LLC)cells were significantly reduced in size,and the survival of the mice was improved.In addition,experiments using a melanoma mouse model showed that baculovirus-infected BMDCs inhibited tumor growth and improved survival compared with controls.Serum alanine aminotransferase(ALT),aspartate aminotransferase(AST)and creatinine levels remained normal in baculovirus-infected BMDC-treated mice.Our findings show that baculovirus-infected DCs induce antitumor immunity and pave the way for the use of this technique as an effective tool for DC immunotherapy against malignancies.展开更多
Natural killer cells （NKs） have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including...Natural killer cells （NKs） have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells （PBMCs）, stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.展开更多
基金a Grant-in-Aid for High Technology Research(No.09309011)from the Ministry of Education,Science,Sports,and Culture,Japanand by a Grant-in-Aid for AIDS research from the Ministry of Health,Labor and Welfare,Japan.
文摘A dendritic cell(DC)vaccine strategy has been developed as a new cancer immunotherapy,but the goal of complete tumor eradication has not yet been achieved.We have previously shown that baculoviruses potently infect DCs and induce antitumor immunity against hepatomas in a mouse model.Baculovirus-infected,bone marrow-derived DCs(BMDCs)display increased surface expression of costimulatory molecules,such as CD80,CD86 and major histocompatibility complex(MHC)classes I and II,and secrete interferons and other proinflammatory cytokines.In this study,we evaluated the induction of antitumor immunity in mice by baculovirus-infected BMDCs against lung cancer and melanoma.After treatment with baculovirus-infected BMDCs,murine lung tumors caused by Lewis lung carcinoma(LLC)cells were significantly reduced in size,and the survival of the mice was improved.In addition,experiments using a melanoma mouse model showed that baculovirus-infected BMDCs inhibited tumor growth and improved survival compared with controls.Serum alanine aminotransferase(ALT),aspartate aminotransferase(AST)and creatinine levels remained normal in baculovirus-infected BMDC-treated mice.Our findings show that baculovirus-infected DCs induce antitumor immunity and pave the way for the use of this technique as an effective tool for DC immunotherapy against malignancies.
基金This work was supported by the National Natural Science Foundation of China （Nos. 81788101, 91542000, 81671558, and 31571440） the Ministry of Science and Technology of China （No. 2016YFC1303503） and Chinese Academy of Sciences （Nos. XDA12020312, XDPB030301, and XDPB030303）.
文摘Natural killer cells （NKs） have a great potential for cancer immunotherapy because they can rapidly and directly kill transformed cells in the absence of antigen presensitization. Various cellular sources, including peripheral blood mononuclear cells （PBMCs）, stem cells, and NK cell lines, have been used for producing NK cells. In particular, NK cells that expanded from allogeneic PBMCs exhibit better efficacy than those that did not. However, considering the safety, activities, and reliability of the cell products, researchers must develop an optimal protocol for producing NK cells from PBMCs in the manufacture setting and clinical therapeutic regimen. In this review, the challenges on NK cell-based therapeutic approaches and clinical outcomes are discussed.
